Le Lézard
Classified in: Covid-19 virus

Global Parkinson's Disease Drug Forecast and Market Analysis to 2029: High Opportunities and High Risks for Disease-Modifying Therapies Entering the PD Market - ResearchAndMarkets.com


The "Parkinson's Disease - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

The global PD market is forecast to experience significant growth during the forecast period; global sales are expected to increase from $3.5B in 2019 to $11.5B in 2029, at a Compound Annual Growth Rate (CAGR) of 12.6%. This growth will be driven by the launch of 17 late-stage pipeline products.

The highest selling drugs are expected to be: Roche/Prothena's PRX-002 followed by Novo Nordisk's Victoza. PRX-002 is a mAb with disease-modifying properties. KOLs were optimistic about this drug and suggested it may revolutionize PD treatment. Also, the MOA of Victoza was highly regarded as a potential neuroprotective drug in addition to its established high safety profile.

Key Highlights

Scope

Key Topics Covered:

1 Parkinson's Disease: Executive Summary

1.1 Parkinson's Market Expected to Grow Significantly, Driven by New Launches

1.2 High Opportunities and High Risks for Disease-Modifying Therapies Entering the PD Market

1.3 Diverse Pipeline Agents Will Partially Address Key Unmet Needs

1.4 The Entry of Novel Biologics and Innovative Delivery Systems Will Shape the PD Market

1.5 What Do Physicians Think?

2 Introduction

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.1.3 Mechanisms of Cell Death

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.5 Epidemiological Forecast for PD (2019-2029)

4.5.1 Diagnosed Prevalent Cases of PD

4.5.2 Sex-Specific Diagnosed Prevalent Cases of PD

4.5.3 Age-Specific Diagnosed Prevalent Cases of PD

4.5.4 Diagnosed Prevalent Cases of PD by HY Clinical Staging

4.5.5 Diagnosed Prevalent Cases of PD by Type

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of Analysis

4.6.4 Strengths of Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 KOL Insights on Disease Management

6 Competitive Assessment

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Effective Treatment of Motor Complications - Dyskinesia, Off-Episodes, Gait, and Balance Problems

7.3 New Therapies for Non-motor Complications - Psychosis and Dementia

7.4 Neuroprotective/Disease-Modifying Agents

7.5 Improved Drug Formulations

8 R&D Strategies

8.1 Overview

8.1.1 Development of Novel Targets ? mAbs Targeting ?-synuclein, and Gene Therapies

8.1.2 Innovative Drug Delivery Systems

8.1.3 Secondary Indications and Drug Repurposing

8.1.4 Clinical Trial Design

8.1.5 Reliable Biomarkers of Disease Progression

8.1.6 Genetic Studies Required to Learn About Genetic Subtypes of PD

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/43zcto

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


These press releases may also interest you

at 06:15
CNFinance Holdings Limited ("CNFinance" or the "Company"), a leading home equity loan service provider in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023...

at 06:05
3EO Health, a "Point of Life" diagnostics company focused on the development of high-performing low-cost molecular diagnostics, is excited to announce the next step in their quest to make molecular testing affordable. Today, the company has published...

at 06:05
Zura Bio Limited ("Zura Bio") a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights. The Company has also...

at 06:05
REX American Resources Corporation ("REX" or the "Company") , a leading ethanol production company, today announced financial and operational results for the Company's full year and fiscal fourth quarter 2023. REX American Resources' Q4 and full...

at 03:00
Caledonia Mining Corporation Plc ("Caledonia" or the "Company")  announces its operating and financial results for the year ended December 31, 2023 (the "Year"). Further information on the financial and operating results for the Year and the quarter...

at 00:01
In advance of the upcoming NAB 2024 show, fan-streaming trailblazer Attention Seekers announced that it has selected Eluvio to provide the back-end technology platform for its next-generation Keystream service, a private press streaming service...



News published on and distributed by: